Paloma Partners’s ImmunityBio IBRX Stock Holding History

Paloma Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-124,080	Closed	-$127K	–	2098
2019 Q2	$127K	Buy	+124,080	New	+$143K	﹤0.01%	1602
2019 Q1	–	Sell	-37,271	Closed	-$43K	–	1794
2018 Q4	$43K	Buy	+37,271	New	+$85.3K	﹤0.01%	1172
2018 Q3	–	Sell	-10,958	Closed	-$34K	–	1715
2018 Q2	$34K	Buy	+10,958	New	+$40.6K	﹤0.01%	1561

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paloma Partners's IBRX Position: Q3 2019 in Review

Paloma Partners sold out of ImmunityBio (IBRX) in Q3 2019, closing a stake of 124,080 shares — an estimated $127K sold.

Paloma Partners first reported a position in IBRX in Q2 2018 and held it in 3 quarters. The position peaked at $127K in Q2 2019. 39 funds tracked by Wall St. Rank hold IBRX as of Q3 2019.

Paloma Partners reported no remaining ImmunityBio position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 124,080 ImmunityBio shares in Q3 2019, an estimated $127K.
Paloma Partners first reported a position in ImmunityBio in Q2 2018 and held it in 3 quarters.
Paloma Partners's ImmunityBio position peaked at $127K in Q2 2019.
39 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.